List of Excipients in Branded Drug CIALIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	CIALIS	tadalafil	0002-4462	CELLULOSE, MICROCRYSTALLINE
Eli Lilly and Company	CIALIS	tadalafil	0002-4462	CROSCARMELLOSE SODIUM
Eli Lilly and Company	CIALIS	tadalafil	0002-4462	FERRIC OXIDE YELLOW
Eli Lilly and Company	CIALIS	tadalafil	0002-4462	HYDROXYPROPYL CELLULOSE
Eli Lilly and Company	CIALIS	tadalafil	0002-4462	HYPROMELLOSE

Cialis Excipient Strategy and Commercial Opportunities in Tadalafil Formulations

Last updated: August 5, 2026

Cialis is an oral tadalafil product whose commercial differentiation historically depended on dose flexibility, once-daily use, and brand recognition rather than a complex excipient platform. The U.S. composition uses conventional immediate-release tablet excipients, leaving commercial opportunity in generic supply, taste-masked dosage forms, orally disintegrating tablets, improved dissolution systems, and patient-friendly low-dose products. Core tadalafil composition and major use patents have expired or reached the end of their effective exclusivity periods, but formulation and manufacturing patents can still affect specific products and jurisdictions.

What excipients are used in Cialis tablets?

Cialis tablets use a conventional compressed-core, film-coated formulation. The U.S. prescribing information identifies the following inactive ingredients:

Formulation component	Excipient	Likely functional role
Tablet core	Lactose monohydrate	Diluent and compression aid
Tablet core	Croscarmellose sodium	Superdisintegrant
Tablet core	Hydroxypropyl cellulose	Binder
Tablet core	Sodium lauryl sulfate	Wetting and dissolution aid
Tablet core	Magnesium stearate	Lubricant
Film coating	Hypromellose	Film-forming polymer
Film coating	Triacetin	Plasticizer
Film coating	Titanium dioxide	Opacifier and color modifier
Film coating	Ferric oxide yellow	Colorant
Film coating	Talc	Anti-tacking and coating aid

The active pharmaceutical ingredient is tadalafil. Cialis is supplied as yellow, film-coated tablets in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths. The formulation is designed for oral administration and does not rely on an extended-release matrix, enteric coating, lipid vehicle, or complex delivery device. [1]

Why does the Cialis formulation use sodium lauryl sulfate?

Tadalafil has low aqueous solubility, making wetting and dissolution relevant to product performance. Sodium lauryl sulfate can improve wetting of hydrophobic drug particles and support more consistent dissolution. Its use also creates formulation-development constraints because excessive surfactant can affect tablet hardness, disintegration, gastrointestinal tolerability, and dissolution profiles.

A generic manufacturer would normally evaluate surfactant level, particle size, granulation method, compression force, and lubricant concentration together. A formulation that matches the Cialis dissolution profile without reproducing the exact excipient quantities can still be acceptable if it meets applicable bioequivalence and quality requirements.

What role does lactose play in Cialis?

Lactose monohydrate is a standard diluent that supports tablet mass, flow, and compressibility. It is commercially available from multiple suppliers and is not, by itself, a meaningful barrier to generic entry. The main technical issue is compatibility with the drug substance, moisture control, and suitability for patients with lactose intolerance or excipient sensitivity.

How does tadalafil’s solubility affect excipient selection?

Tadalafil is generally treated as a poorly water-soluble, orally absorbed drug for formulation-development purposes. Excipient selection therefore focuses on dissolution, wetting, particle-size control, and dose uniformity.

Conventional immediate-release strategy

The lowest-cost strategy is a direct-compression or wet-granulation tablet using:

• A diluent such as lactose, microcrystalline cellulose, or mannitol
• A superdisintegrant such as croscarmellose sodium, crospovidone, or sodium starch glycolate
• A binder such as hydroxypropyl cellulose or povidone
• A surfactant or wetting agent
• A lubricant such as magnesium stearate or sodium stearyl fumarate
• A conventional film-coating system

This approach has the strongest manufacturing economics and the clearest regulatory precedent. It is most appropriate for standard 2.5 mg, 5 mg, 10 mg, and 20 mg generic tablets.

Enhanced-dissolution strategy

Companies seeking a differentiated product can use:

• Micronized or nanomilled tadalafil
• Amorphous solid dispersions
• Polymer-based precipitation inhibitors
• Cyclodextrin complexes
• Spray-dried or hot-melt-extruded dispersions
• Surfactant-polymer combinations
• Porous carriers or co-processed excipients

These systems may reduce dissolution variability or enable smaller dosage forms. They also increase development cost, process-control requirements, analytical burden, and the risk that the product becomes subject to formulation-specific patent claims.

For a conventional abbreviated new drug application, enhanced dissolution alone does not guarantee a commercial advantage. The product must still demonstrate bioequivalence, stability, manufacturability, and acceptable cost.

What commercial opportunities exist for tadalafil excipients?

The strongest opportunities are in dosage-form differentiation and supply-chain substitution rather than ownership of the basic Cialis formulation.

Generic tablet manufacturing

Generic tadalafil tablets are the largest practical excipient opportunity. The formulation is relatively simple, and the active ingredient is available from multiple API manufacturers. Excipient suppliers can compete on:

• Low-moisture lactose and microcrystalline cellulose
• High-functionality superdisintegrants
• Low-shear lubricant systems
• Film-coating premixes
• Direct-compression excipient platforms
• Excipients that support low-dose content uniformity
• Ready-to-use granules for high-throughput manufacturing

The 2.5 mg and 5 mg products present greater content-uniformity sensitivity than the 20 mg strength because the tadalafil load is lower relative to tablet mass.

Orally disintegrating and chewable tadalafil

Taste-masked tablets, orally disintegrating tablets, and chewable products could address patients who have difficulty swallowing conventional tablets. The main excipient requirements are:

• Efficient disintegration with low tablet friability
• Taste masking for tadalafil’s bitter or unpleasant taste
• Saliva-compatible dissolution
• Low hygroscopicity
• Acceptable mouthfeel
• Robust packaging against moisture

Potential technologies include ion-exchange resins, polymeric taste-masking coatings, lipid barriers, cyclodextrins, coated drug particles, and specialized mannitol-based ODT matrices.

A differentiated product may require a new drug application, a 505(b)(2) pathway, or another regulatory route depending on the proposed changes and the reference product. It cannot assume that a new dosage form will qualify for the same abbreviated pathway as a conventional generic tablet.

Pediatric and geriatric dosage forms

Tadalafil has established use in adults for erectile dysfunction and benign prostatic hyperplasia, while other tadalafil products are used for pulmonary arterial hypertension. Pediatric applications would require separate clinical and regulatory justification. The more immediate opportunity is geriatric-friendly administration, including:

• Smaller tablets
• ODTs
• Oral suspensions
• Sprinkle formulations
• Unit-dose sachets
• Low-dose daily products

Suspensions create additional requirements for physical stability, redispersibility, preservative strategy, dosing accuracy, and container compatibility.

Fixed-dose and combination products

Combination products involving tadalafil and other erectile-dysfunction or cardiovascular agents present clinical and regulatory complexity. PDE5 inhibitors also have important contraindications with nitrates and significant interaction considerations. A combination formulation therefore has a higher evidence burden than a simple excipient modification.

The more commercially credible combination opportunity is not necessarily a new tadalafil combination. It may be a co-packaged regimen or adherence-oriented presentation that does not alter the active ingredients or create a new pharmacologic combination.

When did Cialis lose patent and regulatory exclusivity?

Cialis has lost the core exclusivity that supported its branded monopoly in the United States.

Milestone	Approximate timing	Commercial significance
U.S. approval of Cialis	2003	Established tadalafil for erectile dysfunction
Original tadalafil compound/composition patent period	Expired in the late 2010s	Removed the principal compound barrier
Generic tadalafil litigation settlements	2017-2018 period	Allowed earlier staged generic entry
First broad U.S. generic launches	2018	Initiated direct price competition
Once-daily use patent period	Around 2020	Reduced remaining method-of-use protection
Current market position	Post-generic	Brand competes through recognition, distribution, and formulation continuity

The principal U.S. patent associated with tadalafil is U.S. Patent No. 5,859,006. Other patents, including U.S. Patent No. 6,821,975, were associated with tadalafil uses and dosing regimens. Patent term, pediatric extensions, terminal disclaimers, listing status, and settlement provisions must be checked against the specific product and jurisdiction. [2, 3]

What is the Orange Book status of Cialis?

The FDA Orange Book historically listed Cialis-related patents covering tadalafil and specific methods of use. Orange Book listings are relevant to abbreviated new drug applications because an applicant must address listed patents through certification or a statement that the patent has expired.

The commercial significance of Orange Book patents is narrower than the broader tadalafil patent landscape. A formulation or manufacturing patent that is not listed in the Orange Book can still create litigation exposure, but it does not necessarily create the same ANDA certification framework.

Generic applicants commonly use one of four approaches:

1. Paragraph I certification that no patent information is listed.
2. Paragraph II certification that a listed patent has expired.
3. Paragraph III certification that the applicant will wait until patent expiration.
4. Paragraph IV certification that the patent is invalid, unenforceable, or will not be infringed.

For tadalafil, Paragraph IV activity was part of the generic-entry process before the major market openings. Current commercial risk depends on the exact product, remaining listed patents, pediatric exclusivity, and any later-issued formulation patents. [3, 4]

Which companies challenged Cialis patents?

Major generic pharmaceutical companies, including Teva Pharmaceuticals and other ANDA applicants, participated in tadalafil generic litigation and settlement activity. Eli Lilly entered agreements that permitted certain generic tadalafil launches before the full expiration of all asserted patent rights. The timing and scope of individual launches varied by dosage form, indication, and market.

Generic competition now includes products from multiple manufacturers. The relevant competitive comparison is no longer limited to whether a company can obtain approval. It also includes:

• API cost and supply reliability
• Tablet yield and manufacturing speed
• Dissolution performance
• Packaging cost
• Pharmacy contracting
• Wholesale acquisition price
• Authorized-generic relationships
• Ability to supply all four Cialis strengths

Settlement agreements can affect launch dates even after a Paragraph IV challenge. They may also contain restrictions on authorized launches, supply arrangements, or product scope. [5]

How strong is the Cialis patent estate today?

The original Cialis patent estate is materially weaker than it was during brand exclusivity because core compound and major use protections have expired or reached the end of their effective periods. The residual risk is product-specific.

Patent category	Current strategic assessment
Tadalafil compound protection	No longer the principal barrier to U.S. generic entry
Standard immediate-release tablet	Low-to-moderate patent risk, subject to jurisdiction and later patents
Once-daily dosing methods	Historically important; primary U.S. protection reached expiration around 2020
New taste-masked dosage forms	Potentially protectable if technically distinct and non-obvious
ODT or chewable systems	Moderate formulation-patent potential
Nanoparticle or amorphous systems	Higher patent potential, with greater development complexity
Manufacturing processes	Potentially enforceable if process claims are narrow and evidence is available
Device or packaging systems	Relevant only where the product includes protected delivery or packaging technology

A new excipient combination can support patent claims only if it produces a legally meaningful technical distinction. Simply replacing lactose with microcrystalline cellulose or changing one disintegrant generally offers limited patent strength unless the formulation delivers an unexpected and reproducible result.

What formulation patents could protect a new tadalafil product?

Potential claim categories include:

• Tadalafil particle-size distributions
• Specific amorphous tadalafil solid dispersions
• Drug-polymer ratios
• Taste-masking layers
• ODT compositions with defined disintegration times
• Low-dose tablets with improved content uniformity
• Reduced-food-effect formulations
• Oral suspensions with defined particle-size and sedimentation profiles
• Stable liquid formulations
• Manufacturing parameters that produce a defined solid-state form
• Packaging systems that control moisture or light exposure

A strong formulation patent should connect composition to measurable performance. Examples include improved dissolution under defined conditions, reduced variability after storage, enhanced stability, or a clinically relevant pharmacokinetic result. Broad claims covering routine excipient substitutions are vulnerable to obviousness challenges.

How does Cialis compare with Viagra from an excipient and commercial perspective?

Cialis and Viagra occupy the same erectile-dysfunction market but have different active ingredients and product histories.

Factor	Cialis	Viagra
Active ingredient	Tadalafil	Sildenafil citrate
Typical duration	Longer duration of action	Shorter duration of action
Standard strengths	2.5, 5, 10, 20 mg	25, 50, 100 mg
Original sponsor	Eli Lilly	Pfizer
Core market differentiation	Once-daily and longer-duration positioning	Brand recognition and established on-demand use
Generic status	Broad generic competition	Broad generic competition
Excipient opportunity	ODT, taste masking, low-dose daily products	ODT, chewable, taste-masked, rapid-dissolution products
Main formulation issue	Poor aqueous solubility and dose flexibility	Solubility, taste, and rapid administration

Cialis has a stronger formulation rationale for daily low-dose products because the 2.5 mg and 5 mg regimens create opportunities in adherence, tablet size, and dose uniformity. Viagra’s larger dose range creates different opportunities in rapid disintegration and swallowability.

What FDA regulatory issues affect tadalafil excipient strategy?

The FDA generally expects excipients in abbreviated applications to be supported by prior use, acceptable specifications, and appropriate safety data. Key regulatory issues include:

• Inactive Ingredient Database precedent
• Quantity and route-of-administration limits
• Impurity and elemental impurity control
• Residual solvents
• Nitrosamine risk assessment where relevant
• Drug-excipient compatibility
• Dissolution method discrimination
• Stability under long-term and accelerated conditions
• Bioequivalence under the required fasting and fed conditions
• Container-closure protection from moisture and light

A formulation using novel excipients or substantially higher levels than established oral products may require additional toxicology and regulatory justification. The lowest-risk generic strategy is usually a conventional immediate-release composition using well-established oral excipients.

What generic launch risks exist for tadalafil?

The principal launch risks are commercial and technical rather than compound-patent driven.

Commercial risks

• Rapid price erosion after multiple approvals
• Low differentiation among conventional tablets
• Retail and payer substitution
• API price volatility
• Inventory requirements across four strengths
• Channel pressure from online pharmacies
• Competition from sildenafil and other PDE5 inhibitors

Technical risks

• Failure to match reference-product dissolution
• Low-dose content-uniformity failures
• Food-effect differences
• Tadalafil polymorph or particle-size variability
• Tablet sticking or capping during compression
• Coating defects
• Moisture-related stability loss
• Taste-masking failure in ODT or chewable products

Patent and litigation risks

• Later-issued formulation patents
• Process patents asserted against manufacturing sites
• Jurisdiction-specific patent rights
• Settlement restrictions
• Authorized-generic competition
• Claims directed to specific daily-use regimens or patient populations

How large is the commercial exposure to Cialis patent expiry?

Cialis was one of Eli Lilly’s major products before generic entry. Lilly reported Cialis revenue of approximately $2.3 billion in 2017, before full generic erosion. Revenue declined as generic tadalafil entered the U.S. market and competition expanded. [6]

For excipient suppliers and formulation companies, the opportunity is not equivalent to the pre-expiry branded market. The addressable value is distributed across:

• API and finished-dose generic manufacturers
• Contract development and manufacturing organizations
• Film-coating suppliers
• Specialty excipient vendors
• ODT and taste-masking technology providers
• Regional generic companies
• Private-label and online pharmacy channels

The most defensible opportunities are products that reduce manufacturing cost, improve dissolution robustness, enable new dosage forms, or create a differentiated regulatory filing.

Key Takeaways

• Cialis uses a conventional lactose-based, film-coated immediate-release tablet.
• The core excipients are commercially available and do not create a meaningful barrier to standard generic entry.
• Tadalafil’s low solubility supports opportunities in wetting, particle engineering, solid dispersion, and taste-masking technologies.
• The strongest near-term excipient opportunity is generic tablet supply, particularly low-dose 2.5 mg and 5 mg products.
• ODT, chewable, suspension, and other patient-friendly products offer greater differentiation but carry higher regulatory and patent risk.
• Core tadalafil and major U.S. Cialis exclusivity periods have ended or materially declined.
• Orange Book certifications, settlement terms, and later formulation patents remain relevant for product-specific launch planning.
• A formulation patent is strongest when it links a defined excipient system to measurable dissolution, stability, pharmacokinetic, or usability benefits.
• Commercial returns will depend more on manufacturing economics, channel access, and dosage-form differentiation than on ownership of the basic Cialis formulation.

FAQs About Cialis Excipient and Formulation Opportunities

What is the best low-cost excipient platform for generic tadalafil?

A conventional immediate-release tablet using lactose or microcrystalline cellulose, a superdisintegrant, hydroxypropyl cellulose or povidone, a wetting agent, magnesium stearate, and a standard hypromellose coating is the lowest-risk platform.

Can tadalafil be formulated as an orally disintegrating tablet?

Yes. An ODT can use mannitol, crospovidone or croscarmellose sodium, a taste-masking system, and moisture-protective packaging. Bioequivalence, palatability, stability, and regulatory pathway requirements remain central.

Are Cialis excipients protected by patents?

The individual conventional excipients are generally not the commercial barrier. Specific combinations, particle-engineering methods, taste-masking systems, solid dispersions, and manufacturing processes may be patentable.

Is tadalafil suitable for a 505(b)(2) formulation?

A substantially modified dosage form, such as an oral suspension, ODT, or enhanced-dissolution product, may be evaluated under a 505(b)(2) strategy depending on the proposed product and regulatory reliance. A standard equivalent tablet is more likely to follow the ANDA route.

Do Cialis tablets contain lactose?

Yes. The U.S. Cialis label identifies lactose monohydrate as an inactive ingredient. A lactose-free tadalafil product could target patients seeking alternative excipient profiles, but the change would not by itself create a strong patent or clinical advantage.

References

1. U.S. Food and Drug Administration. (2023). Cialis (tadalafil) prescribing information. Eli Lilly and Company.

2. United States Patent and Trademark Office. (1999). U.S. Patent No. 5,859,006: Pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of impotence. U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2009). Submitting a new drug application for a change in dosage form or route of administration. Center for Drug Evaluation and Research.

5. Federal Trade Commission. (2013). Authorized generic drugs: Short-term effects and long-term impact. U.S. Federal Trade Commission.

6. Eli Lilly and Company. (2018). 2017 annual report. Eli Lilly and Company.